{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T07:00:38Z","timestamp":1774767638505,"version":"3.50.1"},"reference-count":13,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,5,13]],"date-time":"2017-05-13T00:00:00Z","timestamp":1494633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate dose\u2013response relationship of <jats:styled-content style=\"fixed-case\">BGG<\/jats:styled-content>492 as add\u2010on therapy to 1\u20133 antiepileptic drugs in patients with partial\u2010onset seizures and to investigate safety and tolerability of <jats:styled-content style=\"fixed-case\">BGG<\/jats:styled-content>492.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a 12\u2010week, randomized, double\u2010blind, placebo\u2010controlled, phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> dose\u2010titration study (core study) with a 30\u2010week, flexible\u2010dose, open\u2010label extension. In the core study, patients were randomized (1:2) to placebo or <jats:styled-content style=\"fixed-case\">BGG<\/jats:styled-content>492 100\u00a0mg <jats:styled-content style=\"fixed-case\">t.i.d.<\/jats:styled-content> in cohort 1, and in cohort 2 patients were randomized (1:4) to placebo or <jats:styled-content style=\"fixed-case\">BGG<\/jats:styled-content>492 150\u00a0mg <jats:styled-content style=\"fixed-case\">t.i.d<\/jats:styled-content>. On completion of the core study, eligible patients entered the extension study. Primary outcome measures were total partial seizure frequency per 28\u00a0days (core study) and safety and tolerability (extension study).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 93 patients were randomized (150\u00a0mg [n\u00a0=\u00a044]; 100\u00a0mg [n\u00a0=\u00a024]; placebo [n\u00a0=\u00a025]), and 81 (87.1%) completed the core study. Fifty\u2010one patients entered and 43 (84.3%) completed the extension study. In the core study, no statistically significant dose\u2013response trend among the <jats:styled-content style=\"fixed-case\">BGG<\/jats:styled-content>492 treatment groups (100 and 150\u00a0mg) was observed at the 4\u2010week double\u2010blind maintenance period (weeks 7\u201310); however, there was higher percent reduction in total partial seizure frequency in the <jats:styled-content style=\"fixed-case\">BGG<\/jats:styled-content>492 150\u00a0mg over placebo groups (37.32%; 95%<jats:styled-content style=\"fixed-case\"> confidence interval [CI]<\/jats:styled-content> \u221218.90, 66.95). Dizziness, somnolence, and fatigue were the most common adverse events (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s), higher in the <jats:styled-content style=\"fixed-case\">BGG<\/jats:styled-content>492 150\u00a0mg group than in the 100\u00a0mg and placebo groups (dizziness: 14 [31.8%] vs. 3 [12.5%] and 1 [4.0%]; somnolence: 7 [15.9%] vs. 1 [4.2%] and 1 [4.0%]; fatigue: 5 [11.4%] vs. 1 [4.2%] and 1 [4.0%]). During the open\u2010label extension study, 39 (76.5%) patients on <jats:styled-content style=\"fixed-case\">BGG<\/jats:styled-content>492 had <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s, and the most commonly experienced <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s were dizziness (14 [27.5%]) and somnolence (9 [17.6%]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Significance<\/jats:title><jats:p>There was no significant dose\u2013response trend in the <jats:styled-content style=\"fixed-case\">BGG<\/jats:styled-content>492 treatment groups (100 and 150\u00a0mg); however, higher percent reduction over placebo was observed in the <jats:styled-content style=\"fixed-case\">BGG<\/jats:styled-content>492 150\u00a0mg group. Safety and tolerability data were consistent with the known safety profile for <jats:styled-content style=\"fixed-case\">BGG<\/jats:styled-content>492, and no new safety risks were identified.<\/jats:p><\/jats:sec>","DOI":"10.1111\/epi.13771","type":"journal-article","created":{"date-parts":[[2017,5,13]],"date-time":"2017-05-13T07:44:37Z","timestamp":1494661477000},"page":"1217-1226","source":"Crossref","is-referenced-by-count":8,"title":["<scp>BGG<\/scp>492 as an adjunctive treatment in patients with partial\u2010onset seizures: A 12\u2010week, randomized, double\u2010blind, placebo\u2010controlled, phase <scp>II<\/scp> dose\u2010titration study with an open\u2010label extension"],"prefix":"10.1111","volume":"58","author":[{"given":"Christian E.","family":"Elger","sequence":"first","affiliation":[{"name":"Department of Epileptology University of Bonn Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Bong","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Neurology Samsung Medical Center Samsung Advanced Institute for Health Sciences &amp; Technology (SAIHST) Sungkyunkwan University Samsung Biomedical Research Institute Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8666-1640","authenticated-orcid":false,"given":"Christian","family":"Brandt","sequence":"additional","affiliation":[{"name":"Bethel Epilepsy Center Mara Hospital Bielefeld Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Mancione","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover New Jersey U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackie","family":"Han","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover New Jersey U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Strohmaier","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,5,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/511S2a"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.00992.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2010.10.027"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7511-11.2.56"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2008.02.066"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12101"},{"key":"e_1_2_7_8_1","unstructured":"AubersonYP.BGG492 a competitive AMPA\/kainate antagonist in clinical development for the treatment of migraine and epilepsy [abstract]. Presented at the European Federation for Medicinal Chemistry 21st International Symposium on Medicinal Chemistry; 5\u20109 September 2010; Brussels Belgium."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13008"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2005.00344.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00049-3"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-009-9131-y"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12504"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.13771","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.13771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T12:23:28Z","timestamp":1695558208000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.13771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,13]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1111\/epi.13771"],"URL":"https:\/\/doi.org\/10.1111\/epi.13771","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,13]]}}}